



FROM:

Padilla Speer Beardsley Inc.
1101 West River Parkway
Minneapolis, MN 55415

CHF Solutions, Inc.
7601 Northland Drive, Suite 170
Brooklyn Park, MN 55428

Nancy A. Johnson, (612) 455-1745
njohnson@psbpr.com
Nick Banovetz, (612) 455-1705
nbanovetz@psbpr.com

Ed Rychlick, (763) 463-4671
rychlick@chfsolutions.com

FOR IMMEDIATE RELEASE

**CHF SOLUTIONS LAUNCHES TWO PRODUCTS TO ADVANCE
AQUAPHERESIS™ THERAPY PERFORMANCE AND SIMPLICITY**

BROOKLYN PARK, MINN. – July 21, 2009 – CHF Solutions has introduced two products in its Aquapheresis therapy product line: a kink-resistant, dual lumen peripheral venous catheter, and an upgrade to the company’s award-winning Aquapheresis Aquadex FlexFlow™ device that automatically limits the fluid removal rate and enhances patient monitoring.

The coiled dual lumen extended length catheter (cdELC) is a peripheral catheter designed to deliver a steady and reliable blood flow in a wide variety of fluid overloaded patients. The 6Fr catheter has unique features, such as a flexible stainless steel coil, an offset tip and a reverse taper, to minimize disruptions to therapy. The catheter combines the steady blood flow of a central venous catheter with the proven advantages of a peripheral catheter profile.

“The cdELC has significantly improved our delivery of Aquapheresis therapy to our patients,” said Ellen M. Amedeo, Heart Failure Program coordinator at St. Luke's Hospital in Bethlehem Pa. “From the physicians who prescribe the therapy, the PICC team who place the catheter, and the nurses who run the therapy, we all are quite pleased with the performance and results.”

Hematocrit monitoring, a standard feature on new Aquapheresis devices and available as an optional upgrade to existing systems, automatically limits the fluid removal rate to help prevent excessive volume depletion due to high fluid removal rates and extended treatment times. This feature enhances monitoring based on each individual patient’s hemodynamic response.

“Hematocrit monitoring gives me confidence that the patient will get the best rate of fluid removal,” said Dr. Andrew Kao, a cardiologist with Cardiovascular Consultants in Kansas City, Mo. “Aquapheresis is very effective in removing excess salt and water, and hematocrit monitoring gives an additional layer of safety in achieving euvolemia in fluid overloaded patients.”

Recently elevated in national treatment guidelines, CHF Solutions’ Aquapheresis therapy is a method to safely and effectively remove the excess salt and water in patients with fluid overload.

(more)

Aquapheresis is available in more than 250 medical centers and outpatient clinics worldwide and more than 22,000 patients have received this therapy to date.

About CHF Solutions, Inc.

CHF Solutions, based in Brooklyn Park, Minn., is a privately held manufacturer of medical devices for cardiac care. The company's mission is to provide medical practitioners with innovative and practical solutions that enable the treatment of patients with unmet clinical needs. For more clinical and corporate information, go to www.chfsolutions.com.

#

Rx only

L5175 Rev. A 07/09